Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant human MSH2 protein.|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 4 publications below|
A suggested positive control for this product is tonsil tissue.
MSH2 is involved in DNA repair as a mismatch repair protein, and mutations of MSH2 are found in approximately 50% of inherited non polyposis colorectal carcinoma. Defects in MSH2 are a cause of hereditary non-polyposis colorectal cancer (HNPCC) (Lynch syndrome). HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. it is characterized by a familial predisposition to early onset colorectal carcinoma (crc) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the western world.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer.
MA1-12621 was used in immunohistochemistry to study the expression of MLH1 and MSH2 in Turkish patients with sporadic colorectal cancer
|Erdamar S,Ucaryilmaz E,Demir G,Karahasanoglu T,Dogusoy G,Dirican A,Goksel S||World journal of gastroenterology (13:4437)||2007|
Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
MA1-12621 was used in immunohistochemistry to study elevated microsatellite alterations and mismatch repair gene expression in prostate cancer
|Burger M,Denzinger S,Hammerschmied CG,Tannapfel A,Obermann EC,Wieland WF,Hartmann A,Stoehr R||Journal of molecular medicine (Berlin, Germany) (84:833)||2006|
Pedigree and genetic analysis of a novel mutation carrier patient suffering from hereditary nonpolyposis colorectal cancer.
MA1-12621 was used in immunohistochemistry to investigate the genetic basis of hereditary nonpolyposis colorectal cancer in a patient with a novel mutation
|Tanyi M,Olasz J,Lukács G,Csuka O,Tóth L,Szentirmay Z,Ress Z,Barta Z,Tanyi JL,Damjanovich L||World journal of gastroenterology (12:1192)||2006|
Different types of microsatellite instability in ovarian carcinoma.
MA1-12621 was used in immunohistochemistry to study different types of microsatellite instability in ovarian carcinoma
|Singer G,Kallinowski T,Hartmann A,Dietmaier W,Wild PJ,Schraml P,Sauter G,Mihatsch MJ,Moch H||International journal of cancer (112:643)||2004|
COCA1; DNA mismatch repair protein Msh2; FCC1; hMSH2; HNPCC; HNPCC1; mutS homolog 2, colon cancer, nonpolyposis type 1; MutS protein homolog 2
COCA1; FCC1; HNPCC; HNPCC1; LCFS2; MSH2